We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serological Assays Assessed for Q Fever

By LabMedica International staff writers
Posted on 24 Oct 2012
Print article
A quality assessment was performed for three different serological methods that are routinely used in the diagnosis of Q fever.

The indirect immunofluorescence assay (IFA) is considered the reference method for diagnosing Q fever, but serology is also performed by complement fixation assay (CFA) or enzyme-linked immunosorbent assay (ELISA), however, comparability between these assays is not clear.

A total of 13 laboratories collaborated in multi-institution study to test the various methods and the results were collated by the Center for Infectious Disease Control, (RIVM; Bilthoven, The Netherlands). The Q fever cases were confirmed either by a positive polymerase chain reaction (PCR) or by seroconversion. In total, the proficiency panel consisted of 25 serum samples: five samples with an intended negative outcome, six samples from acute Q fever patients, and eight serially diluted high-positive sample from a Q fever patient.

The five Dutch laboratories that performed IFA all used the same commercially available IFA (Focus Diagnostics, Cypress, CA, USA). Six laboratories carried out a commercially available CFA (Virion-Serion; Würzburg, Germany), and five participants also performed the Virion-Serion's ELISA and one laboratory used an ELISA from Inverness Medical Innovations, (Waltham, MA, USA). Three national reference laboratories from outside the Netherlands also participated and all used an in-house IFA.

For the diagnosis of Q fever, all assays reached a specificity of 95% to 100% in the samples with an intended negative outcome. All laboratories correctly identified Q fever patients with the algorithm of the methods that were applied. The IFA, ELISA, and CFA values between laboratories using the same methods were within close range, with usually no more than two dilution differences in the reported titer. However, there were differences in sensitivity between the methods.

The IFA proved to be the most sensitive assay in detecting a past Q fever infection. All laboratories using IFA detected both immunoglobulin G (IgG) phase I antibodies (titers ranged from 1:32 to1:256) and phase II antibodies (titers ranged from1:128 to 1:512) in samples in these patients. The ELISA yielded mostly intermediate IgG phase II responses, and four of six laboratories using CFA detected only low titers of 1:10 to1:20 against phase II. No IgM response was detected with any of the applied assays.

Q fever is a highly contagious zoonotic disease caused by Coxiella burnetii, a Gram-negative obligate intracellular bacterium. Since 2007, the Netherlands has been faced with the largest outbreak of Q fever ever reported, with over 4,000 notified cases. The authors concluded that IFA, ELISA, and CFA are all suitable serodiagnostic assays for diagnosing acute Q fever. ELISAs can be an alternative for screening large sample numbers. The IFA appears to be the method of choice when high sensitivity is required, especially against phase I, and for example identifying chronic Q fever. The study was published on October 5, 2012, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Netherlands Center for Infectious Disease Control
Focus Diagnostics
Virion-Serion


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.